# Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

> **NCT00519090** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 6 (actual)

## Conditions studied

- Myelogenous Leukemia

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Nilotinib (AMN107)

## Key facts

- **NCT ID:** NCT00519090
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** This study was terminated due to limited enrollment.
- **Last updated:** 2011-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00519090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00519090, "Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00519090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*